立方制药(003020.SZ)：拟向鹿灵葵花转让“美沙拉秦肠溶片”药品上市许可持有人及相关权益

Core Viewpoint - Lifan Pharmaceutical (003020.SZ) plans to transfer its marketing authorization holder (MAH) rights and related interests for the drug Mesalazine Enteric-Coated Tablets (0.5g) to Luling Kuihua for a total fee of 34 million yuan (including tax) [1] Group 1 - The total fee for the transfer of the product rights has been agreed upon by both parties at 34 million yuan, which reflects the actual value of the product rights and market conditions [1]